(800) 574 – 6320
Request a call back
-
Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index…
-
Mentor Capital Cancer Immunotherapy Index Posts 11% Annual Loss in 2012 and Adds Companies for 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index declined (-10.9%) during 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For 2012 the biotech indices averaged a 32.7%…
-
Mentor Capital Cancer Immunotherapy Index Gains 47% During First Quarter
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 47.3% during the first quarter of 2012. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first…
-
Mentor Capital Reports Mid-Year Profits for 2011
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (OTC Markets: MNTR) today reported financial results for the semi-annual period ending June 30, 2011. The company announced earnings of $0.04 per basic and diluted share for the six-month period. The six months of earnings, which calculates to an $0.08 per share annualized rate, follows the $0.09 per basic share …
-
Mentor Capital Cancer Immunotherapy Index Outpaces Biotechs on Second Anniversary
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 85.30% during the twenty-four months since its creation on July 10, 2009. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE…
-
Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval of $93,000 Provenge Immunotherapy Treatment by Dendreon for Prostate Cancer
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports correlated gains across the 10 trading companies of the Mentor Capital Cancer Immunotherapy Index with the recent 6.6% one-day price appreciation of Index pioneer and market leader, Dendreon (NASDAQ:DNDN). The Dendreon price appreciation follows the Medicare Evidence Development &…
-
Mentor Capital Takes Investment Position in Each of 10 Cancer Immunotherapy Index Companies
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) has completed the set-up and initial funding of the Cancer Immunotherapy Index Fund. Through the CII Fund, Mentor Capital has now taken an initial equity position in each of the ten companies that make up Mentor Capital's proprietary Cancer Immunotherapy Index. The equally weighted CI Index was…
-
Mentor Capital Retains Network 1 Financial Securities for Comprehensive Investment Banking Services
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) today announced the engagement of Network 1 Financial Securities, Inc. to provide investment banking, investor relations and financial advisory services. Network 1 Financial Securities, Inc. is headquartered in Red Bank, New Jersey and is an independent full-service securities firm. …
-
Mentor Capital, Inc. Initiates Trading at $1.05/sh (P/E of 2.7x)
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets: MNTR) began trading under its new symbol MNTR, at an initial Asking price of $1.05 per share. The initial price calculates to a current P/E ratio of 2.7x on a diluted basis. The Company holds 99 cents per diluted share in cash, investment in securities, and notes or receivables from its investments. Mentor Capital, Inc.…